Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquine
Open Access
- 8 January 2021
- journal article
- research article
- Published by Taylor & Francis in Immunological Medicine
- Vol. 44 (3) , 204-210
Abstract
Systemic lupus erythematosus (SLE) preferentially affects women of childbearing age. Miscarriages or fetal death, intrauterine growth restriction (IUGR), preterm delivery, preeclampsia and disease flares complicate pregnancy in SLE patients. Treatment is challenging due to the need to prevent disease exacerbations and limit obstetrical complications, while showing an acceptable safety profile for both the mother and the fetus. We collected data from 74 pregnancies in 53 SLE patients prospectively followed in a dedicated ‘Pregnancy at risk’ outpatient clinic from 2003 to 2019. Out of 74, 45 pregnancies patients were treated with hydroxychloroquine (HCQ). Mothers under HCQ therapy (HCQ+ patients) and those who did not receive HCQ (HCQ−) were homogeneous in terms of age and comorbidities. Disease activity prior to conception was slightly higher in HCQ+ patients. No significant difference was observed in terms of obstetrical history. In patients achieving a viable pregnancy, the rate of IUGR (4/39, 10% in HCQ+ vs 8/25, 32%, in HCQ− patients, p < .05) was significantly lower in HCQ+ patients. Conversely, HCQ+ patients displayed a significantly longer time to delivery (37.8 ± 1.72 vs. 36.3 ± 4.11 in HCQ− patients, p < .05). HCQ is safe in pregnant patients with SLE and protects against obstetrical complications.Keywords
This publication has 50 references indexed in Scilit:
- Women, Kidney Disease, and PregnancyAdvances in Chronic Kidney Disease, 2013
- Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individualsArthritis Research & Therapy, 2012
- High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndromeActa Obstetricia et Gynecologica Scandinavica, 2011
- Mechanism of Endosomal TLR Inhibition by Antimalarial Drugs and ImidazoquinolinesThe Journal of Immunology, 2011
- A Systematic Review and Meta-Analysis of Pregnancy Outcomes in Patients with Systemic Lupus Erythematosus and Lupus NephritisClinical Journal of the American Society of Nephrology, 2010
- Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drugBlood, 2010
- Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic reviewAnnals of the Rheumatic Diseases, 2010
- Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseasesPediatric Rheumatology, 2009
- Maternal and foetal outcomes in pregnant patients with active lupus nephritisLupus, 2009
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006